Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Participants with the variants did not respond differently to other common diabetes treatments, including sulfonylureas, metformin and DPP-4i
GLP-1s and Addiction The authors of GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer , appearing in October 2025 in JES, point out that the World Health Organization reported 890 million adults and 60 million children and adolescents had obesity in 2022 globally
These findings have expanded how doctors think about using these medications
Background Substance use disorder is a leading public health concern, affecting approximately 40 million people worldwide
E., Lavell, J., and Foreman, R
FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
US$ 21.16
US$ 21.69
US$ 26.24
US$ 21.34
